ID: ALA2385584

Max Phase: Preclinical

Molecular Formula: C24H22N6O

Molecular Weight: 410.48

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cn1cc2c(-c3cnn4cc(-c5ccc(N6CCOCC6)cc5)cnc34)cccc2n1

Standard InChI:  InChI=1S/C24H22N6O/c1-28-16-22-20(3-2-4-23(22)27-28)21-14-26-30-15-18(13-25-24(21)30)17-5-7-19(8-6-17)29-9-11-31-12-10-29/h2-8,13-16H,9-12H2,1H3

Standard InChI Key:  WIJRGIUWBLWHOK-UHFFFAOYSA-N

Associated Targets(non-human)

Bone morphogenetic protein 4 32 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 410.48Molecular Weight (Monoisotopic): 410.1855AlogP: 3.79#Rotatable Bonds: 3
Polar Surface Area: 60.48Molecular Species: NEUTRALHBA: 7HBD: 0
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 1.53CX LogP: 3.64CX LogD: 3.64
Aromatic Rings: 5Heavy Atoms: 31QED Weighted: 0.45Np Likeness Score: -1.66

References

1. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR..  (2013)  Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.,  23  (11): [PMID:23639540] [10.1016/j.bmcl.2013.03.113]

Source